Weight loss drugs linked to higher risk of eye damage in diabetic patients

A recent study published in JAMA Ophthalmology indicates that GLP-1 receptor agonists (GLP-1 RAs), like semaglutide (Ozempic), may double the risk of neovascular age-related macular degeneration in diabetic patients after six months of use, with the risk increasing threefold after 30 months; older diabetic patients or those with a history of stroke face an even higher risk, prompting calls for caution when prescribing these drugs, though Novo Nordisk maintains that clinical trials have not shown a causal relationship and that patient safety remains a top priority.

Analysis

A large-scale Canadian study published in JAMA Ophthalmology indicates a significant association between the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), predominantly semaglutide (Ozempic), and an increased risk of neovascular age-related macular degeneration (AMD) in diabetic patients. The research, which examined medical data for over 1 million Ontario residents with diabetes and specifically identified 46,334 patients on GLP-1 RAs (average age 66, with 97.5% taking semaglutide), found that use for at least six months doubled the risk of developing AMD compared to matched controls not taking the drugs. This risk escalated to over three times for those on GLP-1 RAs for more than 30 months, with older diabetic patients and those with a history of stroke demonstrating an even higher susceptibility. An accompanying editorial suggested this could affect 'as many as one in 1,000 GLP-1 RA users,' potentially impacting a 'sizable group of patients.' Novo Nordisk (NVO), manufacturer of Ozempic and Wegovy, stated its extensive clinical development programs have not shown any observable treatment difference for macular degeneration compared to placebo and does not conclude a causal relationship at this time. Regulatory bodies, such as the UK's MHRA, are reviewing the emerging evidence but currently assert that the benefits of GLP-1 RAs outweigh potential risks for licensed indications. Nevertheless, these findings, along with a moderately negative sentiment signal (-0.5 for NVO) and a market impact score of 0.55, introduce a noteworthy consideration for the outlook of this drug class and its leading manufacturers.

Key Decisions for Investors

• Investors should closely monitor further research and regulatory responses concerning the potential link between GLP-1 RAs and AMD, as this could influence prescribing patterns and future market penetration for key drugs like Ozempic and Wegovy, impacting manufacturers such as Novo Nordisk (NVO).
• Consideration should be given to the potential for increased scrutiny, possible labelling adjustments, or shifts in physician recommendations if the link is further substantiated, which may affect long-term sales forecasts for this drug class, particularly within the diabetic patient segment and potentially extending to the weight-management market.
• The moderately negative sentiment for NVO (-0.5) and the cautious tone surrounding these findings warrant careful observation of how this new data influences physician, patient, and payer perception of these widely utilized medications, potentially creating headwinds or requiring further risk mitigation by manufacturers.